Background: Alzheimer’s disease (AD) is the most common form of dementia
that seriously affects daily life. Even if AD pathogenesis is still subject of debate, it is generally
accepted that cerebral cortex plaques formed by aggregated amyloid-β (Aβ) peptides
can be considered a characteristic pathological hallmark. It is well known that metal ions
play an important role in the aggregation process of Aβ. Methods: This review focuses on
the anti-Aβ aggregation activity of chelating ligands as well as on the use of metal complexes
as diagnostic probes and as potential drugs. Conclusion: While chelating agents,
such as curcumin or flavonoid derivatives, are currently used to capture metal ions responsible
for Aβ aggregation, the potential application of platinum, ruthenium and cobalt complexes,
among others, of several heterocyclic ligands, represents a promising new strategy
to fight AD.
Keywords: Alzheimer’s Disease, metal ions, metal complexes, AD drugs, anti-Aβ aggregating agents, imaging.
Rights & PermissionsPrintExport